Stool Studies for Assessing Inflammatory Processes

Initial Stool Testing Approach

Fecal calprotectin demonstrates 93-95% sensitivity and 91-96% specificity for differentiating IBD from non-IBD diagnoses, making it the recommended initial screening test 1
The American Gastroenterological Association recommends that values <50 μg/g are reassuring and point toward non-inflammatory etiologies 2, 1
Values between 50-250 μg/g are challenging to interpret, as mild elevation may reflect non-specific low-grade inflammation 2
Thresholds of 200-250 μg/g predict endoscopic remission in both ulcerative colitis and Crohn's disease 2
For patients under age 45 with diarrhea, fecal calprotectin specifically excludes inflammatory bowel disease 3

The American College of Gastroenterology recommends stool testing for Clostridioides difficile is mandatory in all new presentations of diarrhea, regardless of antibiotic use history 4, 5, 6
Stool culture and ova/parasites testing should be performed selectively based on geographic area and relevant clinical features 4, 3
Fecal occult blood testing is recommended for screening purposes in all patients with suspected inflammatory processes 3

Values ≤40.5 μg/g predict histological remission with 41% sensitivity and 100% specificity 2
Values <60 μg/g predict deep remission in ulcerative colitis with 86% sensitivity and 87% specificity 2
For mild symptoms with intermediate values (50-250 μg/g), serial calprotectin monitoring at 3-6 month intervals facilitates early recognition of disease flares 2
If a flare is suspected based on rising calprotectin, endoscopy with biopsies and/or dedicated small bowel imaging in Crohn's disease should be pursued 2

C-reactive protein shows poor sensitivity, with up to 15-20% of patients failing to mount a CRP response despite active inflammation 2, 1
Therapeutic decisions should never be based on clinical considerations alone without objective inflammatory markers 2, 7
The combination of serum CRP and fecal calprotectin provides more comprehensive assessment than either marker alone 2, 7

Do not dismiss intermediate calprotectin values (50-250 μg/g) without clinical correlation, as upper normal limits vary and mild elevation may indicate subclinical inflammation 2
Do not rely solely on clinical disease activity indices without objective inflammatory markers, as symptom severity may not correlate with inflammatory activity 2, 7
Do not assume normal CRP excludes active inflammation, given the 15-20% false-negative rate 2, 1

In elderly patients (>60 years), maintain high suspicion for alternative diagnoses including colorectal cancer, ischemic colitis, segmental colitis associated with diverticulosis, NSAID-induced pathology, radiation colitis, or microscopic colitis 4, 5, 6
Fecal calprotectin or lactoferrin helps prioritize elderly patients with low probability of IBD for endoscopic evaluation 4

Patients with hematochezia or chronic diarrhea with intermediate to high suspicion for IBD should undergo colonoscopy regardless of stool test results 4
Alarm features or acute symptom onset in previously well-controlled disease mandate endoscopic evaluation 2, 3
Elevated fecal calprotectin >200-250 μg/g requires endoscopic confirmation with biopsies from both affected and normal-appearing areas 2, 1